person · Reporting owner

RIEDEL NORBERT G

Disclosed activity across 5 companies

Tapewire entity: 903
SEC CIK: 0001161662

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aptinyx Inc.APTX · Entity 120922	Director · EXECUTIVE CHAIRMAN OF THE BOD	January 03, 2023	January 05, 2023
Eton Pharmaceuticals, Inc.ETON · Entity 4598	Director	July 31, 2026	August 04, 2026
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aptinyx Inc.

Report date January 03, 2023 · Filed January 05, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2033-01-02	Direct	420,000	Reported balance After 2023-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-03 · Grant · Acquired 420,000 · Balance 420,000 F1: This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months.

Eton Pharmaceuticals, Inc.

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table II · derivative / convertible security	Direct	10,000	Reported balance After 2026-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 10,000 · Balance 10,000 F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Filing footnotes · ownership attribution and instrument terms

F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Jazz Pharmaceuticals plc

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	6,923	Ending reported balance After 2026-08-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 8,615 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 6,923 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Ordinary SharesSEC Table I · non-derivative	Indirectby Trust	10,630	Reported balance Holding disclosure · report date 2026-08-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 10,630

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 139,867 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50	Direct	Reported balance After 2017-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45	Direct	Reported balance After 2017-02-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91	Direct	Reported balance After 2017-02-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82	Direct	Reported balance After 2017-02-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 46,092 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2026 Filed Sep 2, 2026 21:31 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	1,692	$241.39	$408,431.88	Disclosure SEC source: 0001161662-26-000008 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,923 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 31, 2026 Filed Sep 2, 2026 21:31 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	14	$244.64	$3,425.02	Disclosure SEC source: 0001161662-26-000008 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,615 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 05, 2026 Filed Aug 7, 2026 21:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,605	$0.00	$0.00	Disclosure SEC source: 0001161662-26-000005 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,629 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. F2 · balance_after: Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family. Read SEC document
July 31, 2026 Filed Aug 4, 2026 20:56 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantCommon Stock · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-025696 · rdgdoc.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document
April 21, 2026 Filed Apr 22, 2026 20:40 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	19,655	$0.00 Strike: $8.61	$0.00	Disclosure SEC source: 0001437749-26-013041 · rdgdoc.xml · derivative · entry 5 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,655 shares Expires 2031-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 21, 2026 Filed Apr 22, 2026 20:40 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0001437749-26-013041 · rdgdoc.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 21, 2026 Filed Apr 22, 2026 20:40 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionCommon Stock	19,655	$8.61	$169,229.55	Disclosure SEC source: 0001437749-26-013041 · rdgdoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 21, 2026 Filed Apr 22, 2026 20:40 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionCommon Stock	12,500	$7.31	$91,375.00	Disclosure SEC source: 0001437749-26-013041 · rdgdoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2026 Filed Mar 2, 2026 22:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,415	$0.00 Strike: $138.08	$0.00	Disclosure SEC source: 0001161662-26-000002 · edgardoc.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,415 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017. Read SEC document
February 27, 2026 Filed Mar 2, 2026 22:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,415	$192.00	$655,680.00	Disclosure SEC source: 0001161662-26-000002 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,024 Read SEC document
February 27, 2026 Filed Mar 2, 2026 22:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	3,415	$138.08	$471,543.20	Disclosure SEC source: 0001161662-26-000002 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2026 Filed Feb 5, 2026 22:18 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	OtherEmployee Stock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0001437749-26-003230 · rdgdoc.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-02-12 Read SEC document
February 03, 2026 Filed Feb 5, 2026 22:18 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	OtherCommon Stock	30,000	$4.42	$132,600.00	Disclosure SEC source: 0001437749-26-003230 · rdgdoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:09 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantRestricted Stock Units · Derivative	7,757	$0.00	$0.00	Disclosure SEC source: 0001437749-26-001301 · rdgdoc.xml · derivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,253 Underlying: Common Stock · 7,757 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:09 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantEmployee Stock Option (Right to Buy) · Derivative	12,196	$0.00 Strike: $15.47	$0.00	Disclosure SEC source: 0001437749-26-001301 · rdgdoc.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,496 Underlying: Common Stock · 12,196 shares Expires 2036-01-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027. Read SEC document
August 08, 2025 Filed Aug 11, 2025 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	1,805	$111.25	$200,805.89	Disclosure SEC source: 0001765581-25-000082 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,024 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family. Read SEC document
August 07, 2025 Filed Aug 11, 2025 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	3,507	$0.00	$0.00	Disclosure SEC source: 0001765581-25-000082 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,829 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · derivative · entry 6 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $3.78	$0.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · derivative · entry 5 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	27,400	$0.00 Strike: $3.58	$0.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,400 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionCommon Stock	25,000	$3.47	$86,750.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · nonDerivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionCommon Stock	50,000	$3.78	$189,000.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:22 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	Exercise / conversionCommon Stock	27,400	$3.58	$98,092.00	Disclosure SEC source: 0001437749-25-000466 · rdgdoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2025 Filed Jan 6, 2025 21:20 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantEmployee Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $13.00	$0.00	Disclosure SEC source: 0001437749-25-000462 · rdgdoc.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest equally on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 3, 2026. Read SEC document
August 06, 2024 Filed Aug 6, 2024 22:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	1,484	$111.35	$165,243.40	Disclosure SEC source: 0001765581-24-000077 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,322 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 02, 2024 Filed Aug 6, 2024 22:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	3,731	$0.00	$0.00	Disclosure SEC source: 0001765581-24-000077 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,806 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:24 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerStock Option (Right to Buy) · Derivative	95,242	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090806 · ownership.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,242 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:24 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090806 · ownership.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:24 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	46,092	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090806 · ownership.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:30 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-070725 · ownership.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,553 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document
February 13, 2024 Filed Feb 15, 2024 21:15 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock Option (Right to buy) · Derivative	30,000	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0001437749-24-004358 · rdgdoc.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,555 Underlying: Common Stock · 30,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 13, 2025. Read SEC document
August 14, 2023 Filed Aug 15, 2023 21:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,241	$138.16	$171,454.20	Disclosure SEC source: 0001765581-23-000088 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,705 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.68 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 11, 2023 Filed Aug 15, 2023 21:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	3,075	$0.00	$0.00	Disclosure SEC source: 0001765581-23-000088 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,946 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	13,780	$0.00 Strike: $32.60	$0.00	Disclosure SEC source: 0000899243-23-015179 · doc4.xml · derivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,780 Underlying: Common Stock · 13,780 shares Expires 2033-06-07 F2 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015179 · doc4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,092 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
March 03, 2023 Filed Mar 3, 2023 21:10 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock Option (Right to buy) · Derivative	25,000	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0001493152-23-006677 · ownership.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,555 Underlying: Common Stock · 25,000 shares Expires 2033-02-19 F1 · date: Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023. F2 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20,2024. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:17 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	420,000	$0.00 Strike: $0.36	$0.00	Disclosure SEC source: 0001415889-23-000545 · form4-01052023_090146.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · EXECUTIVE CHAIRMAN OF THE BOD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
August 08, 2022 Filed Aug 9, 2022 22:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,089	$152.32	$165,876.92	Disclosure SEC source: 0001765581-22-000096 · edgardoc.xml · nonDerivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,871 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	8,000	$0.00 Strike: $55.28	$0.00	Disclosure SEC source: 0001765581-22-000096 · edgardoc.xml · derivative · entry 5 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,000 shares Expires 2023-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vested over three years from the Vesting Commencement Date, with 1/3 that vested on the first anniversary of the Vesting Commencement Date and the remainder vested in 24 equal monthly installments thereafter. Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,561	$0.00	$0.00	Disclosure SEC source: 0001765581-22-000096 · edgardoc.xml · nonDerivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	8,000	$155.87	$1,246,920.00	Disclosure SEC source: 0001765581-22-000096 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,399 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.80.00 to $156.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	8,000	$55.28	$442,240.00	Disclosure SEC source: 0001765581-22-000096 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:49 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	23,459	$0.00 Strike: $24.35	$0.00	Disclosure SEC source: 0000899243-22-022836 · doc4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 Underlying: Common Stock · 23,459 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
February 07, 2022 Filed Feb 28, 2022 21:34 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock Option (Right to buy) · Derivative	50,000	$0.00 Strike: $3.78	$0.00	Disclosure SEC source: 0001493152-22-005618 · ownership.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,555 Underlying: Common Stock · 50,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7,2023. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:31 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionRestricted Stock Units · Derivative	14,270	$0.00	$0.00	Disclosure SEC source: 0000899243-22-001199 · doc4.xml · derivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 14,270 RSUs vested on January 4, 2022, the third anniversary of the vesting commencement date of January 4, 2019. F2 · derivative.expiration_date: 14,270 RSUs vested on January 4, 2022, the third anniversary of the vesting commencement date of January 4, 2019. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:31 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	14,270	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-001199 · doc4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. Read SEC document
December 06, 2021 Filed Dec 8, 2021 21:16 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	100,000	$2.23	$223,000.00	Disclosure SEC source: 0001415889-21-005779 · form4-12082021_011216.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Riedel 2020 Irrevocable Trust Disclosed balance after: 100,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
December 02, 2021 Filed Dec 7, 2021 21:16 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	475,000	$0.00 Strike: $2.28	$0.00	Disclosure SEC source: 0001415889-21-005740 · form4-12072021_011257.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2031-12-01 F1 · derivative.exercise_date: This option shall vest 25% on December 2, 2022, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:38 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,306	$147.96	$193,235.76	Disclosure SEC source: 0001765581-21-000108 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,399 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
July 29, 2021 Filed Aug 2, 2021 22:25 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,246	$0.00	$0.00	Disclosure SEC source: 0001765581-21-000081 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,705 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.